The patient support landscape in 2026 looks fundamentally different from what existed even a decade ago, driven by rapid shifts in specialty medicine.
Manufacturers have significantly expanded investment in digital engagement, specialty pharmacy partnerships, educational resources, reimbursement support, and personalised programs designed to help patients navigate increasingly complex therapies.
Those investments reflect the changing realities of specialty care, where treatment now regularly extends well beyond the point of writing a prescription.
Specialty therapies account for more than half of all U.S. drug spending, with many new specialty therapies expected to enter the market over the next several years.
As innovation has accelerated across the pharmaceutical sector, patient support infrastructure has been forced to adapt alongside it, creating both new opportunities and new organisational challenges.
For many years, patient support discussions centred on whether the right capabilities were in place to help patients overcome barriers to starting and staying on therapy.
Increasingly, as Jennifer Wagner, SVP of Client Solutions at Momentum Life Sciences, argues, the conversation is shifting from building support to connecting support in a meaningful way.
As treatments become more individualised, patient journeys grow more complex, with patients managing complicated schedules, self-monitoring requirements, caregiver involvement, and multiple transitions throughout therapy.
Patients interact with an ecosystem spanning healthcare providers, reimbursement specialists, specialty pharmacies, clinical educators, digital platforms, and manufacturer-sponsored programs across the course of their treatment.
Each interaction serves a distinct purpose, yet patients rarely experience these capabilities one at a time — they experience how those capabilities come together, or fail to, throughout their journey.
Traditional patient support capabilities including access support, reimbursement services, affordability programs, and clinical services continue to play essential roles in helping patients begin therapy successfully.
What has changed significantly is the environment in which those capabilities now operate, particularly as educational, emotional, and practical barriers increasingly influence whether patients initiate and remain engaged with therapy over time.
Organisations are investing not only in expanding patient support capabilities but also in understanding how those capabilities work together across the entire patient journey.
That shift is influencing how patient engagement programs are designed, how responsibilities are shared across partners, and how continuity is created throughout the overall patient experience.
During launch planning, organisations are now considering which points in the journey create drop-off risk, when human engagement is most meaningful, and how digital touchpoints should complement rather than compete with personal interactions.
Artificial intelligence, predictive analytics, workflow automation, and connected data are giving organisations greater visibility into patient needs than at any previous point in the industry’s history.
Technology can help identify critical moments and equip support teams with meaningful context, while human expertise translates that context into conversations that are timely, relevant, and responsive to patient needs.
Rather than viewing technology and human engagement as separate strategies, many organisations are beginning to treat them as complementary capabilities that address complexity at different levels of the patient experience.
Patients facing uncertainty rarely benefit from another notification alone — more often, they need clarity, confidence, and guidance that helps them understand what comes next in their treatment.
Success in patient support is increasingly measured not only by the services organisations provide, but by how effectively those services create a coordinated, connected experience from the patient’s perspective.